ABCL 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-05-11

• •our expectations regarding the success, clinical advancement, and market acceptance of our internal pipeline of drug candidates, including expectations regarding the preliminary, topline, or early-stage clinical data for ABCL635, as well as our antibody discovery and development capabilities;

• •our estimates of market opportunity and forecasts of market growth may prove to be inaccurate, and even if these markets achieve the forecasted growth, our drug candidates may fail to achieve sufficient market acceptance or adoption;

• •our ability to achieve projected discovery, preclinical development, and clinical milestones for our internal programs, including the topline data from the Phase 2 trial anticipated in the third quarter of 2026 for ABCL635, as well as our partners’ ability to achieve projected discovery and develop…

• •our ability to leverage our full platform capabilities - from target identification to investigational new drug, or Investigational New Drug (“IND”), application submission and to clinical development - to advance our internal pipeline of drug candidates, as well as to support our partners;

• •our ability to develop and commercialize the drugs we discover, both internally and with our partners, on a timely basis or at all;

相对上期删除的文字 · 来源:10-Q · 2025-11-06

• •our expectations regarding the rate and degree of market acceptance of our antibody discovery and development capabilities;

• •our expectations regarding the quality of our antibody discovery and development capabilities and technological capabilities, the advancement of internal programs, and their acceptance by new and existing partners in our industry;

• •our partners’ ability to achieve projected discovery and development milestones and other anticipated key events, including commercial sales resulting in royalties owed to us, in the expected timelines or at all;

• •our ability to provide our partners with a full solution from target identification to investigational new drug, or Investigational New Drug (“IND”), application submission;

• •our partners’ ability to develop and commercialize a molecule discovered by us, on a timely basis or at all;

相对上期新增的文字 · 来源:10-Q · 2026-05-11

• There was no change in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

相对上期删除的文字 · 来源:10-Q · 2025-11-06

• The Company completed implementation of its new enterprise resource planning (“ERP”) system in the nine months ended September 30, 2025. The new ERP system replaces our legacy consolidated financial accounting module and is designed to accurately maintain our financial records for reporting operatin…

• Except for the implementation of the ERP system, there were no changes in our internal controls over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal controls o…

相对上期新增的文字 · 来源:10-Q · 2026-05-11

• In the pending matter Sabariah Schrader, Executrix of the Estate of John William Schrader et al. v. Carl Lars Genghis Hansen, et al., the Company filed a Notice of Application seeking to dismiss certain Company affiliates from the matter. No hearing date has been set. All co-defendants have been ser…

相对上期删除的文字 · 来源:10-Q · 2025-11-06

• The Company continues to protect its intellectual property against Bruker Cellular Analysis. Fact discovery of the patent infringement litigation against Bruker has closed and an eight (8) day jury trial has been scheduled for January 2026. The Company maintains its belief in the merits of its case …

• The appeal filed by Bruker regarding IPR2021-1249 to the United States Court of Appeals for the Federal Circuit (CAFC) occurred in May 2025. The U.S. Patent Trial and Appeal Board (PTAB) rejected all of Bruker’s arguments and now the CAFC has confirmed that all challenged claims of AbCellera’s ‘408 …

• In the pending matter Sabariah Schrader, Executrix of the Estate of John William Schrader et al. v. Carl Lars Genghis Hansen, et al., the Company filed a Notice of Application seeking to dismiss certain Company affiliates from the matter. No hearing date has been set. All co-defendants have been ser…

相对上期新增的文字 · 来源:10-Q · 2026-05-11

• We have, and continue to receive, revenue from our partnership contracts and are eligible to receive future milestones and royalties related to potential future success of antibodies that we have discovered under past and existing agreements. We are unable to predict whether and the extent to which …

• •expand our discovery, development, clinical and regulatory capabilities;

• •advance our current and future drug candidates through clinical trials;

• •the initiation and advancement of internal programs and marketing activities associated therewith;

• •the receipt of potential future payments from partners related to milestones, royalties, and licensing;

相对上期删除的文字 · 来源:10-Q · 2025-11-06

• During the years ended December 31, 2020, 2021 and 2022 we generated revenue related to royalty payments upon net sales of antibodies that we discovered. In 2021 and 2022, these royalty payments related to our partnership with Lilly upon sales of bamlanivimab and bebtelovimab, antibodies designed to…

• We have, and continue to receive, other forms of revenue from our partnership contracts and are eligible to receive future milestones and royalties related to potential future success of antibodies that we have discovered under past and existing agreements. We are unable to predict whether and the e…

• •our rate of progress in selling access to our discovery and development capabilities, the initiation and advancement of internal programs and marketing activities associated therewith;

• The various ways we could raise additional capital carry potential risks. If we raise funds by issuing equity securities, dilution to our shareholders would result. Any preferred equity securities issued also would likely provide for rights, preferences or privileges senior to those of holders of ou…

• •our ability to increase awareness of the capabilities of our technology and solutions;